Skip to main content
TipRanks
Go Ultimate75% OFF

Xeris Pharmaceuticals (XERS) Stock Statistics & Valuation Metrics

1,121 Followers

Total Valuation

Xeris Pharmaceuticals has a market cap or net worth of $3.04B. The enterprise value is $1.91B.

Market Cap
$3.04B
Enterprise Value
$1.91B

Share Statistics

Xeris Pharmaceuticals has 182,700,040 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
182,700,040
Owned by Insiders
4.85%
Owned by Institutions
38.13%

Financial Efficiency

Xeris Pharmaceuticals’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 8.89%.

Return on Equity (ROE)
0.04
Return on Assets (ROA)
0.00
Return on Invested Capital (ROIC)
8.89%
Return on Capital Employed (ROCE)
0.09
Revenue Per Employee
670.91K
Profits Per Employee
1,273.563
Employee Count
435
Asset Turnover
0.76
Inventory Turnover
0.78

Valuation Ratios

The current PE Ratio of Xeris Pharmaceuticals is -415.46. Xeris Pharmaceuticals’s PEG ratio is 0.04.

PE Ratio
-415.46
PS Ratio
8.27
PB Ratio
61.79
Price to FCF
41.91
Price to Operating Cash Flow
40.93
PEG Ratio
0.04

Income Statement

In the last 12 months, Xeris Pharmaceuticals had revenue of 291.85M and earned 554.00K in profits. Earnings per share was 0.00.

Revenue
291.85M
Gross Profit
238.43M
Operating Income
24.90M
Pretax Income
554.00K
Net Income
554.00K
EBITDA
12.71M
Earnings Per Share (EPS)
0.00

Cash Flow

In the last 12 months, operating cash flow was 73.65M and capital expenditures -1.03M, giving a free cash flow of 72.62M billion.

Operating Cash Flow
73.65M
Free Cash Flow
72.62M
Free Cash Flow per Share
0.40

Dividends & Yields

Xeris Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
2.39%
Earnings Yield
-0.22%

Stock Price Statistics

Beta
0.82
52-Week Price Change
129.48%
50-Day Moving Average
10.40
200-Day Moving Average
7.83
Relative Strength Index (RSI)
85.41
Average Volume (3m)
2.77M

Important Dates

Xeris Pharmaceuticals upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 10, 2027
Ex-Dividend Date
―

Financial Position

Xeris Pharmaceuticals as a current ratio of 2.19, with Debt / Equity ratio of 275.86%

Current Ratio
2.19
Quick Ratio
1.57
Debt to Market Cap
0.03
Net Debt to EBITDA
-5.77
Interest Coverage Ratio
0.86

Taxes

In the past 12 months, Xeris Pharmaceuticals has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Xeris Pharmaceuticals EV to EBITDA ratio is 119.41, with an EV/FCF ratio of 43.22.

EV to Sales
8.52
EV to EBITDA
119.41
EV to Free Cash Flow
43.22
EV to Operating Cash Flow
42.62

Balance Sheet

Xeris Pharmaceuticals has $131.08M in cash and marketable securities with $226.07M in debt, giving a net cash position of -$94.98M billion.

Cash & Marketable Securities
$131.08M
Total Debt
$226.07M
Net Cash
-$94.98M
Net Cash Per Share
-$0.52
Tangible Book Value Per Share
-$0.30

Margins

Gross margin is 84.44%, with operating margin of 12.70%, and net profit margin of -1.76%.

Gross Margin
84.44%
Operating Margin
12.70%
Pretax Margin
-1.76%
Net Profit Margin
-1.76%
EBITDA Margin
7.14%
EBIT Margin
3.74%

Analyst Forecast

The average price target for Xeris Pharmaceuticals is $17.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$17.17
Price Target Upside
3.04% Upside
Analyst Consensus
Strong Buy
Analyst Count
6
Revenue Growth Forecast
38.37%
EPS Growth Forecast
63.43%

Scores

Smart Score
8
AI Score
64